(IN BRIEF) Almirall’s new data highlights the alarming lack of awareness regarding actinic keratosis (AK), a common precancerous dermatological condition linked to sun exposure, with more than one-third of affected individuals unaware of its causes. The survey, conducted across Spain, … Read the full press release
(IN BRIEF) Almirall, a leading biopharmaceutical company specializing in medical dermatology, has reported its full-year 2023 financial results, showcasing a 4% year-on-year growth in net sales driven by the strong performance of its European Dermatology business. The company’s total EBITDA … Read the full press release
Posted in Business, Economy, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Carlos Gallardo, Dermatology, Financial, investment
(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release
Posted in Business, Denmark, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Denmark, Dermatology, Dr. Karl Ziegelbauer, IL-21, NN-8828, Novo Nordisk, partnership, sustainability
(IN BRIEF) Almirall S.A., a global pharmaceutical company specializing in medical dermatology, has confirmed its involvement in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, taking place from January 8th to 11th, 2024. Carlos Gallardo, Chairman and CEO … Read the full press release
Posted in Business, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Spain, Technology
Tagged 42nd Annual J.P. Morgan Healthcare Conference, Almirall, Carlos Gallardo, San Francisco
(IN BRIEF) EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, have entered into a license agreement to develop bispecific antibodies for up to three undisclosed target pairs. Almirall … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, antibodies, Dr. Chengbin Wu, EpimAb, Fabs-In-Tandem Immunoglobulin (FIT-Ig®), Karl Ziegelbauer, Multiple Targets, partnership, sustainability
(IN BRIEF) Almirall, a global biopharmaceutical company specializing in medical dermatology, has entered into an agreement with Centrient Pharmaceuticals, a leader in sustainable biosynthetic pharmaceuticals, to establish a dedicated innovation lab at Almirall’s R&D center in Sant Feliu de Llobregat, … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Barcelona, Centrient Pharmaceuticals, Innovation Lab, Jorge Gil-Martinez, Karl Ziegelbauer, medical dermatology, partnership, R&D center, Rex Clements, sustainability
Durch diese Lizenzvereinbarung mit Ablexis erhält Almirall Rechte zur Nutzung der AlivaMab®-Maustechnologie für die Forschung, Entwicklung und Vermarktung von Antikörpern AlivaMab Mouse bietet hochmoderne transgene Mausplattformen, die humane therapeutische Antikörper mit hoher Vielfalt liefern Almirall wird mit AlivaMab Discovery Services … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Spain, Technology
Tagged Ablexis, AlivaMab Discovery Services, AlivaMab Mouse, Almirall, Antikörpermedikament, Antikörpertherapeutika, Biopharmazeutika, dermatologische Erkrankungen, Dr. Thomas Huber, Hautgesundheit, humantherapeutische Antikörper, Justin Mika, Larry Green, Lizenzvereinbarung, schwere Hauterkrankungen
Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and commercialisation of antibodies AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering highdiversity human therapeutic antibodies Almirall will partner with AlivaMab … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain, Technology
Tagged Ablexis, AlivaMab Discovery Services, AlivaMab Mouse, Almirall, antibody drug, antibody therapeutics, biopharmaceutical, dermatological conditions, Dr. Thomas Huber, human therapeutic antibodies, Justin Mika, Larry Green, licensing agreement, severe skin diseases, skin health
These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim to identify new biosignatures and treatments for skin cancer and atopic dermatitis AlmirallShare is responsible for 50% of the private-public … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Almirall, AlmirallShare, atopic dermatitis, dermatological conditions, dermatological research, Dermatology, Dublin City University, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, IDIBAPS, inflammatory diseases, Maribel Crespo, medical dermatology, molecular mechanisms, open innovation platform, Prof. Dr. Lluís Puig, Prof. Silvia Vidal, Prof. Tarl Prow, skin cancer, skin carcinoma, skin health, skin immune cell composition, skin transcriptome, skin tumor, Squamous cell Carcinoma, systemic biomarkers, systemic therapy, topical drugs, University College Dublin, University of Namur, University of Sheffield, University of South Australia, University of Turin
Most of the 64 million COPD patients around the world, including over 2 million in Spain, must contend with breathlessness, excessive mucus, chronic cough and other debilitating symptoms throughout 24hours a day The World Health Organization estimates that COPD kills … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?